Drug Trial Radar · NCT07795268
Study to Evaluate the Efficacy and Safety of 177Lu-NYM032 Injection in Participants With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Nov 13, 2026
Primary completion
Nov 30, 2028
Study completion Aug 31, 2029
Sponsor
- Lead sponsor
- Norroy Bioscience Co., LTDIndustry
- Sponsor type
- Industry
- First posted
- Aug 31, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to compare overall survival (OS) in patients with progressive PSMA-positive mCRPC who receive 177Lu-NYM032 in addition to best supportive/best standard of care versus patients treated with best supportive/best standard of care alone.
Conditions
- Prostate Cancer
Interventions
177Lu-NYM032 injectionDrug
Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles.
Best supportive/best standard of careOther
Best supportive/best standard of care as defined by the local investigator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: From date of randomization until date of death from any cause, assessed up to 36months (estimated final OS analysis)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.